Notice of Intent To Grant an Exclusive License; Adaptive Phage Therapeutics, Inc.

Riepilogo

The Department of the Navy hereby gives notice of its intent to grant Adaptive Phage Therapeutics, Inc. a revocable, nonassignable, exclusive license to practice worldwide the Government owned inventions described in U.S. Provisional Patent Application 62/353,517, filed 22 June 2016 and entitled "Bacteriophage compositions and methods of selection of components against specific bacteria" as well as any issued patent, divisional or continuation from that and related foreign filings in the field of antibiotics and drug-resistant bacteria control.